FLEXIQULE®

NATURAL JOINT SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D
CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

FLEXIQULE® (Boswellia Extract) in the Supplementary Management of Osteoarthritis: A Supplement Registry

Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Cesarone MR, Hosoi M, Errichi M, Francis S, Cornelli U.

Internationally published clinical study on knee osteoarthritis patients with FLEXIQULE® shows:

51% Improvement in physical functions

19% Improvement in karnofsky scale score

Reduction in joint pain & stiffness



Minerva Med. 2014 Dec;105(6 Suppl 2):9-16.

ABSTRACT

The aim of the present pilot, registry study was an assessment in a supplement study of FLEXIQULE® (standardized Boswellia Phytoextract™) capsules in the supplementary management of patients with symptomatic knee osteoarthritis (OA) also treated with the "standard management" (SM) in comparison with a group of patients only managed with SM.

RESULTS

Twenty-seven registry subjects using the supplement+SM and 28 using only SM completed the registry; at inclusion, the two groups were comparable including Karnofsky scale, WOMAC Score and the Treadmill Test. The subjects completing the registry 24 preferred to use the combination SM and the supplement. Routine blood tests were normal at inclusion and did not significantly vary at 4 weeks. The Karnofsky Scale at 4 weeks was improved in both groups: from 74.3;3.1 to 88.9;5.3 ($p<0.05$) in the Boswellia group in comparison with a variation from 75.3;5.2 to 79.4;3.3 ($p<0.05$) in the SM. The effects of the supplement were significantly higher ($p<0.05$). The WOMAC Score was decreased significantly more in the supplement+SM group in comparison with controls considering pain, stiffness and physical functions ($p<0.05$). Social/emotional functions improved better with the supplement ($p<0.05$). Both groups improved their walking distance at 4 weeks. The improvement was higher ($p<0.05$) in the Boswellia group. The need for other drugs or tests during the registry period was reduced more in the supplement group ($p<0.05$). The difference between SM and the supplementation associated to SM was significant in favor of the supplementation with Boswellia for all target measurements evaluated in the registry at 4 weeks.

CONCLUSION

In conclusion, even with a more prolonged supplementation, FLEXIQULE® shows to be safe and well tolerated.

FLEXIQULE®

NATURAL JOINT SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D
CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

Supplementary Management of Osteoarthritis (OA) with the Pharma-standard Supplement: FLEXIQULE® (Boswellia Extract) a 12 Week Registry

Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Hu S, Ippolito E.

Internationally published clinical study on knee osteoarthritis patients with FLEXIQULE® shows:

59% Improvement in physical functions

26% Improvement in karnofsky scale score

Reduction in joint pain & stiffness



Minerva Gastroenterol Dietol. 2015 Oct 22

ABSTRACT

This registry study assessed the pharma-standard supplement FLEXIQULE® (Boswellia extract in capsules) in the management of symptoms associated to osteoarthritis (OA) also managed with the 'standard management' (SM) in comparison with a group of patients managed only with SM. The 12- week registry included patients with symptomatic knee arthrosis. They were able to walk on a treadmill for a walking test and to complete the WOMAC questionnaire.

RESULTS

32 patients used the supplement and 34 acted as controls (SM). No safety problems were observed. At 12 weeks, the Karnofsky scale was significantly improved in both groups: the variation was higher ($p<0.05$) in the supplement group. The WOMAC score was decreased significantly more in the supplement+SM group in comparison with controls considering pain, stiffness and physical functions ($p<0.05$). For social and emotional functions the decrease in score was also more evident in the supplement group ($p<0.05$). Both groups improved in pain-free and total walking distance at 12 weeks. Pain-free walking distance (treadmill) was higher ($p<0.05$) with the supplement (from 93.4; 11.6 m to 271.3;19.3 m) than in controls (from 90.5;13.5 m to 158.3;22.3)($p<0.05$). The improvement in total walking distance was also higher in the supplement group ($p<0.05$) (from 164.3;23.2 to 322.3;22.3 m) in comparison with the SM- only group (from 158.3;18,4 to 240.2;19.3 m). The need for concomitant drugs and medical attention during the registry was reduced more in the supplement group ($p<0.05$).

CONCLUSION

In conclusion, the difference between SM and the FLEXIQULE® + SM was in favour of the management with the supplement for all target measurements. The product is safe and well tolerated.

ALEU119040014

FLEXIQULE®

NATURAL JOINT SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

Hand 'Stress' Arthritis in Young Subjects: Effects of FLEXIQULE® (Pharma-standard Boswellia Extract)

Belcaro G, Feragalli B, Cornelli U, Dugall M.

Internationally published clinical study on hand stress arthritis patients with FLEXIQULE® shows:

- **67%** Reduction in hand stress within 2 weeks
- **71%** Reduction in hand joints hyperthermic area
- **68%** Reduction in pain

Significantly reduces hand stress



Minerva Gastroenterol Dietol. 2015 Oct 22.

ABSTRACT

This case report (supplement registry study) evaluated subjects with painful 'stress' arthritis of the hand mainly localized at the joints. The patients received a suggestion to follow a rehabilitation plan (standard management; SM). A second group also used the same SM in association with the oral, pharma-standard supplement FLEXIQULE® (Alchem) a new standardized, phytosomal preparation manufactured from the Boswellia plant, which can be used for self-management in inflammatory conditions (150 mg / 3 times daily).

RESULTS

The two resulting registry groups included 12 subjects using SM+FLEXIQULE® and 11 controls (SM only). The groups were comparable. Serology showed no significant alterations: only ESR was slightly elevated (minimal elevation). After 2 weeks, the ESR was normal in the supplement group and mildly elevated in controls ($p<0.05\%$). The decrease in hyperthermic areas was greater/faster ($p<0.05$) in the supplement group. The identification of a working stress and the localization to the dominant hand was comparable in both groups. At 2 weeks, the decrease in pain was significantly faster and more important with the supplement ($p<0.05$). The hand became more usable in time and the score was better with the supplement ($p<0.05$). No supplemented patient had to use other drugs, while in the control group 3 subjects eventually used NSAIDs to control pain and stiffness and one used corticosteroids.

CONCLUSION

In conclusion, the natural extract FLEXIQULE® was effective in controlling work-related hand stress arthritis (without inflammatory signs) over a 2 weeks period, better than only standard management.

ALEUI19040014

FLEXIQULE®

NATURAL JOINT SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

Management of Osteoarthritis (OA) with the Pharma-standard (PS) Supplement FLEXIQULE® (Boswellia): A 6-month Registry. Safety and Long-term Efficacy

Belcaro G., Dugall M., Luzzi R., Peterzan P. Irvine3 labs, Dpt Sc Med Or Biotec, Ch-Pe University

Internationally published clinical study on osteoarthritis patients with FLEXIQULE® shows:

3.6 Times increase in pain free walking distance

2.3 Times increase in total walking distance

Helps improve physical mobility



International Journal of Pharma Standard (PS) Supplements, June 2016

ABSTRACT

This registry study is assessing this new pharma-standard supplement FLEXIQULE® (Boswellia in soft gel capsules) in the evolution and management of symptoms associated to osteoarthritis also managed with a 'standard management' (SM). A comparison group of patients was managed only with the SM (according to the Merck Manual). The 12-week registry included patients able to walk on a treadmill for a standardized walking test and to complete the WOMAC questionnaire (relative to the most common symptoms).

RESULTS

32 patients used the supplement and 34 acted as controls (SM). No safety problems were observed in 12 weeks; the Karnofsky scale was significantly improved in both groups: the variation (improvement) was higher ($p<0.05$) in the supplement group. The WOMAC score was decreased more in the Supplement + SM group in comparison with controls (considering pain, stiffness and physical functions) ($p<0.05$). For social and emotional functions the decrease in score was also more evident in the FLEXIQULE® group ($p<0.05$). Both groups improved in pain-free and total walking distance at 12 weeks. Pain-free walking distance (treadmill) was higher ($p<0.05$) with the supplement than in controls. The improvement in total walking distance was also higher in the supplement group ($p<0.05$) in comparison with SM. The need for concomitant drugs use and for medical attention during the registry was reduced more with the supplement ($p<0.05$).

CONCLUSION

In conclusion, the difference between SM and FLEXIQULE® + SM was in favour of the management with the supplement for all target measurements. The brand is safe and well-tolerated.

FLEXIQULE®

NATURAL JOINT SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

FLEXIQULE® Safety Study: Non-interference with Anticoagulants & Antiplatelet Agents

Luzzi R., Hu S., Belcaro G., Dugall M., Peterzan P. Irvine3 Labs, Dept Sc Med Or Biotec, Ch-Pe University

Internationally published clinical study on non-Interference with anti-coagulants & anti-platelet agents

FLEXIQULE® has no Interference with anti-coagulants and anti-platelet agents.

No significant change in bleeding time before and after taking FLEXIQULE®

No significant change in INR value before and after taking FLEXIQULE®

Safety study (No drug interaction)



International Journal of Pharma Standard (PS) Supplements, June 2016

ABSTRACT

This registry study is assessing this new pharma-standard supplement FLEXIQULE® (Boswellia in soft gel capsules) in the evolution and management of symptoms associated to osteoarthritis also managed with a 'standard management' (SM). A comparison group of patients was managed only with the SM (according to the Merck Manual). The 12-week registry included patients able to walk on a treadmill for a standardized walking test and to complete the WOMAC questionnaire (relative to the most common symptoms).

RESULTS

32 patients used the supplement and 34 acted as controls (SM). No safety problems were observed in 12 weeks; the Karnofsky scale was significantly improved in both groups: the variation (improvement) was higher ($p<0.05$) in the supplement group. The WOMAC score was decreased more in the Supplement + SM group in comparison with controls (considering pain, stiffness and physical functions) ($p<0.05$). For social and emotional functions the decrease in score was also more evident in the FLEXIQULE® group ($p<0.05$). Both groups improved in pain-free and total walking distance at 12 weeks. Pain-free walking distance (treadmill) was higher ($p<0.05$) with the supplement than in controls. The improvement in total walking distance was also higher in the supplement group ($p<0.05$) in comparison with SM. The need for concomitant drugs use and for medical attention during the registry was reduced more with the supplement ($p<0.05$).

CONCLUSION

In conclusion, FLEXIQULE® – even in a limited study – do not change the antiplatelet action of the most common antiplatelet agents and do not seem to alter, in stable patients, the value of anticoagulant treatment after two weeks of supplementation.

ALEUI19040014

FLEXIQULE®

NATURAL JOINT SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D
CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

Inflammatory Markers Variation in 3 Months with FLEXIQULE® (CRP, ESR, Oxstress)

Dugall M., Luzzi R., Hu S. Irvine3 labs, Dept Sc Med Or Biotec, Ch-Pe University

Internationally published clinical study on inflammatory markers with FLEXIQULE®

53
CARR units reduced

64%
Reduction in inflammatory marker C-Reactive Protein (CRP) in 4 weeks

Significantly reduces ESR after 4 weeks

Helps Reduce Inflammatory Markers



International Journal of Pharma Standard (PS) Supplements, June 2016

ABSTRACT

This satellite study evaluates the variations in CRP in 32 subjects treated for knee osteoathrosis with a new anti-inflammatory agent (FLEXIQULE®, Alchem) at the standard dosage; this product includes Boswellia as the main component. A comparable group of 30 subjects treated with the standard management (SM; including NSAIDs if needed) according to the Merck Manual (12th edition) was studied. The decrease in CRP was significantly larger ($p<0.05$) at each weekly measurement. The variations in ESR (in a second group 12 patients treated with FLEXIQULE® vs 11 comparable controls using the SM) that was also significant at 3 and 4 weeks ($p<0.05$). Finally oxstress (FRAS, System, Parma) measured in CARR units in this same group, decreased from 388;22 to 335;21 CARR units in the FLEXIQULE® group vs a minor change from 383;16 to 376;22 CARR units in controls ($p<0.05$).

CONCLUSION

In conclusion, FLEXIQULE® helps in reduction of inflammatory markers like CRP, ESR and Oxidative Stress.

ALEUI19040014